ALC Stock Overview
Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.33|
|52 Week High||AU$0.48|
|52 Week Low||AU$0.18|
|1 Month Change||-15.58%|
|3 Month Change||-14.47%|
|1 Year Change||54.76%|
|3 Year Change||638.64%|
|5 Year Change||209.52%|
|Change since IPO||400.00%|
Recent News & Updates
|ALC||AU Healthcare Services||AU Market|
Return vs Industry: ALC underperformed the Australian Healthcare Services industry which returned 58.3% over the past year.
Return vs Market: ALC exceeded the Australian Market which returned 11.8% over the past year.
|ALC Average Weekly Movement||6.5%|
|Healthcare Services Industry Average Movement||8.2%|
|Market Average Movement||8.3%|
|10% most volatile stocks in AU Market||15.9%|
|10% least volatile stocks in AU Market||3.6%|
Stable Share Price: ALC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ALC's weekly volatility (7%) has been stable over the past year.
About the Company
Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; and ExtraMed, a patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services.
Alcidion Group Fundamentals Summary
|ALC fundamental statistics|
Is ALC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALC income statement (TTM)|
|Cost of Revenue||AU$3.02m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0021|
|Net Profit Margin||-8.67%|
How did ALC perform over the long term?See historical performance and comparison
Is Alcidion Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ALC (A$0.33) is trading above our estimate of fair value (A$0.08)
Significantly Below Fair Value: ALC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ALC is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: ALC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALC is overvalued based on its PB Ratio (7.5x) compared to the AU Healthcare Services industry average (4.4x).
How is Alcidion Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ALC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALC's is expected to become profitable in the next 3 years.
Revenue vs Market: ALC's revenue (20.7% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: ALC's revenue (20.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALC's Return on Equity is forecast to be low in 3 years time (9.6%).
How has Alcidion Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALC is currently unprofitable.
Growing Profit Margin: ALC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALC is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare ALC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (33.1%).
Return on Equity
High ROE: ALC has a negative Return on Equity (-4.96%), as it is currently unprofitable.
How is Alcidion Group's financial position?
Financial Position Analysis
Short Term Liabilities: ALC's short term assets (A$30.3M) exceed its short term liabilities (A$13.0M).
Long Term Liabilities: ALC's short term assets (A$30.3M) exceed its long term liabilities (A$164.0K).
Debt to Equity History and Analysis
Debt Level: ALC is debt free.
Reducing Debt: ALC has no debt compared to 5 years ago when its debt to equity ratio was 0.08%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ALC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ALC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.6% per year.
What is Alcidion Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Kate Quirke has been Chief Executive Officer and Executive Director of Alcidion Group Ltd. since July 3, 2018 and has been its Managing Director since January 25, 2019. Ms. Quirke served as Chief Execu...
CEO Compensation Analysis
Compensation vs Market: Kate's total compensation ($USD437.44K) is about average for companies of similar size in the Australian market ($USD553.04K).
Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.
Experienced Management: ALC's management team is considered experienced (2.7 years average tenure).
Experienced Board: ALC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.
Alcidion Group Limited's employee growth, exchange listings and data sources
- Name: Alcidion Group Limited
- Ticker: ALC
- Exchange: ASX
- Founded: 2000
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$340.622m
- Shares outstanding: 1.05b
- Website: https://www.alcidion.com
- Alcidion Group Limited
- 9 Yarra Street
- Level 10
- South Yarra
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/29 15:57|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.